Overview of Dr. Schram
Dr. Alison Schram is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, New York-Presbyterian Hospital, and New York-Presbyterian Hospital. She received her medical degree from Perelman School of Medicine at the University of Pennsylvania and has been in practice 5 years. She is one of 497 doctors at Memorial Sloan Kettering Cancer Center and one of 377 doctors at New York-Presbyterian Hospital who specialize in Oncology. She has more than 60 publications and over 500 citings.
Office
160 East 53rd Street
New York, NY 10022
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2018
Brigham and Women's HospitalResidency, Internal Medicine, 2012 - 2015
Perelman School of Medicine at the University of PennsylvaniaClass of 2012
Certifications & Licensure
FL State Medical License 2021 - Present
NY State Medical License 2015 - 2026
CT State Medical License 2023 - 2025
NJ State Medical License 2019 - 2025
MA State Medical License 2014 - 2015
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) Start of enrollment: 2015 Jan 01
- A Study of LY3405105 in Participants With Advanced Cancer Start of enrollment: 2019 Jan 31
Publications & Presentations
PubMed
- Efficacy of Zenocutuzumab inFusion-Positive Cancer.Alison M Schram, Koichi Goto, Dong-Wan Kim, Teresa Macarulla, Antoine Hollebecque
The New England Journal of Medicine. 2025-02-06 - Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma.Sujana Movva, Kenneth Seier, Viswatej Avutu, Lauren B Banks, Jason Chan
Clinical Cancer Research. 2024-12-16 - Emerging Tumor-Agnostic Molecular Targets.Dedipya Bhamidipati, Alison M Schram
Molecular Cancer Therapeutics. 2024-11-04
Journal Articles
- Article Widespread Selection for Oncogenic Mutant Allele Imbalance in CancerSarat Chandarlapaty, Alison M Schram, David M Hyman, David B Solit, ScienceDirect
- Genome Doubling Shapes the Evolution and Prognosis of Advanced CancersAlison M Schram, Jose Baselga, Mark E Robson, David B Solit, Zsofia K Stadler, Nature
Press Mentions
Phase 2 eNRGy Trial: Zenocutuzumab Shows Efficacy in NRG1 Fusion–Positive NSCLCFebruary 10th, 2025- Zenocutuzumab Effective Against NRG1 Fusion CancersFebruary 7th, 2025
- New Bispecific Shrinks NRG1 Fusion-Positive Lung, Pancreatic TumorsFebruary 5th, 2025
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
